Gerresheimer (ETR:GXI) PT Set at €97.00 by Berenberg Bank

Berenberg Bank set a €97.00 ($102.11) target price on Gerresheimer (ETR:GXIGet Rating) in a research note released on Thursday morning, Borsen Zeitung reports.

A number of other brokerages also recently issued reports on GXI. JPMorgan Chase & Co. set a €66.30 ($69.79) price target on shares of Gerresheimer in a research report on Wednesday. The Goldman Sachs Group set a €110.00 ($115.79) price target on shares of Gerresheimer in a research report on Thursday, April 7th. Credit Suisse Group set a €94.00 ($98.95) price target on shares of Gerresheimer in a research report on Tuesday, June 14th. Finally, Deutsche Bank Rese… set a €115.00 ($121.05) price objective on shares of Gerresheimer in a research note on Friday, April 8th.

Shares of ETR GXI opened at €64.20 ($67.58) on Thursday. The company has a market capitalization of $2.02 billion and a P/E ratio of 24.79. Gerresheimer has a 52-week low of €53.45 ($56.26) and a 52-week high of €99.40 ($104.63). The company has a debt-to-equity ratio of 112.42, a quick ratio of 0.37 and a current ratio of 0.75. The company’s 50 day moving average price is €68.51 and its 200-day moving average price is €72.03.

Gerresheimer Company Profile (Get Rating)

Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements.

Read More

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.